Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by davgroon Mar 06, 2024 10:40am
232 Views
Post# 35917983

RE:RE:I'm sorry what happened?

RE:RE:I'm sorry what happened?
woundedknee wrote:
Wow! ATE has to repay 20 million plus 4 million interesr and not subject to appeal. This story just keeps getting better and better,,,for the shorts. GL Mugsy

Its a lot worse than investors understand.  The judgement was $24 million in USD or the equivalent of about $32 million in CAD.  Terms of payment are unknown but I would expect that payment must be made to Nuance soon.

As of December 31st, 2023 the company had about $24 million CAD in cash, cash equivalents and term deposits.  That is a shortfall of over $8 million CAD with respect to the Nuance payment owing.  Where are they going to get that $8 million CAD from ?  Not from warrant holders as I doubt that many executed their warrants at the early warrant exercise price.  A best effort public offering would be highly discounted at this point.

Unless a white knight swoops in to save the day ATE may have seen its last day as a going concern regardless of the potential success of the phase II trial.  You will continue to see a slow decline in share price until management issues their next press release with an actual concrete plan for moving forward.

JMO 
<< Previous
Bullboard Posts
Next >>